Due to the broad applicability of Chlorogen's technology platform across multiple market sectors, Chlorogen has the ability to develop a deep and valuable product pipeline. Chlorogen's management has implemented a strategy that allows Chlorogen to build such a pipeline while ensuring that its resources remain focused to achieve success.

• Chlorogen is focused on co-development of proprietary products for the human therapeutics market. Utilizing the unique strengths of the CTT™ platform to focus on difficult-to-produce proteins, such as TGF-ß's, will create clear competitive advantage in the marketplace.
• Co-development will allow Chlorogen to bundle its strengths of gene/protein expression and manufacturing with those of its partners in drug discovery and market channel access.
• To leverage the broad applicability of CTT, Chlorogen is monetizing the technology in non-core markets through outlicensing. This strategy is providing early revenues and generates additional working capital to support the primary therapeutic business.